A5063002442- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Axon Guidance and Neuronal Signaling
- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Angiogenesis and VEGF in Cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Cancer Mechanisms and Therapy
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Advanced Breast Cancer Therapies
- Cancer-related gene regulation
- Neuroendocrine Tumor Research Advances
- AI in cancer detection
- Flavonoids in Medical Research
- Ubiquitin and proteasome pathways
- Peroxisome Proliferator-Activated Receptors
Queen's University Belfast
2013-2022
Singapore General Hospital
2022
National Cancer Centre Singapore
2020-2021
Genome Institute of Singapore
2020
Universidade de São Paulo
2020
King Abdullah International Medical Research Center
2019
Universiti Sains Malaysia
2018
Pakistan Atomic Energy Commission
2018
Atomic Energy (Canada)
2018
National University of Singapore
2008-2017
Hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide. In heterogeneous group hepatocellular carcinomas, those with characteristics embryonic stem-cell and progenitor-cell gene expression are associated worst prognosis. The oncofetal SALL4, a marker subtype progenitor-like features, poor prognosis potential target for treatment.We screened specimens obtained from patients primary SALL4 carried out clinicopathological analysis. Loss-of-function studies were...
EphA2, a member of the Eph receptor tyrosine kinases family, is an important regulator tumor initiation, neovascularization, and metastasis in wide range epithelial mesenchymal cancers; however, its role colorectal cancer recurrence progression unclear.EphA2 expression was determined by immunohistochemistry stage II/III tumors (N = 338), findings correlated with clinical outcome. The correlation between EphA2 stem cell markers CD44 Lgr5 examined. migration/invasion assessed using panel KRAS...
Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion patients with high-risk stage II/III colorectal cancer will relapse. Thus, novel therapeutic strategies are needed for early-stage cancer. Residual micrometastatic disease from primary tumor is major cause patient
Background Gastric cancer is a leading cause of cancer-related mortality, and current treatment outcomes for advanced disease remain poor. HER2 has been identified as potential candidate targeted therapy in gastric cancers displaying gene amplification protein overexpression. Aims To study the prevalence rate amplification/overexpression local population, determine concordance between various modalities. Methods 128 samples were analysed by fluorescence (FISH) chromogenic (CISH) situ...
Gastric carcinogenesis has been well documented in the step-wise histopathological model, known as Correa pathway. Several biomarkers including CD44, Musashi-1 and CD133 have reported putative stem cell (PSC) markers. We investigated expression of PSC markers relation to gastric prognosis chemoresponse. Immunohistochemistry staining was performed cancer (GC) clinical specimens representing different steps samples taken before after neoadjuvant chemotherapy with docetaxel, cisplatin...
We developed an analytic strategy that correlates gene expression and clinical outcomes as a means to identify novel candidate oncogenes operative in breast cancer. This analysis, followed by functional characterization, resulted the identification of Jumonji Domain Containing 6 (JMJD6) protein driver oncogenic properties cancer.Through microarray informatics, Cox proportional hazards regression was used analyze correlation between distant metastasis-free survival (DMFS) patients 14...
Metastasis accounts largely for the high mortality rate of colorectal cancer (CRC) patients. In this study, we performed comparative proteome analysis primary CRC cell lines HCT-116 and its metastatic derivative E1 using 2-D DIGE. We identified 74 differentially expressed proteins, many which function in transcription, translation, angiogenesis signal transduction, or cytoskeletal remodeling pathways, are indispensable cellular processes involved cascade. Among these stathmin-1 (STMN1) was...
To compare the rejection rates of non-small cell lung cancer (NSCLC) samples obtained by differing sampling methods for testing Sanger sequencing epidermal growth factor receptor (EGFR) mutations. assess association between unsatisfactory outcomes and quantity DNA extracted from cytological versus histological samples.Six hundred seventy NSCLC referred to our centre 2008 2010 were reviewed as a consequence sample rejection, presence EGFR mutations, methods, genotyping rate.Eighty rejected in...
// Zenobia C. D’Costa 1 , Catherine Higgins Chee Wee Ong Gareth W. Irwin David Boyle Darragh G. McArt Karen McCloskey Niamh E. Buckley Nyree T. Crawford Lalitha Thiagarajan 3 James Murray 2 Richard D. Kennedy Karl A. Mulligan 4 Paul Harkin J.J. Waugh Chris J. Scott 5 Manuel Salto-Tellez Williams and B. Mullan Centre for Cancer Research Cell Biology, Queen’s University Belfast, UK Biomedical Science Institute, Trinity College Dublin, Green, Dublin 2, Ireland School of Biological...
Abstract Objective Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial a single-arm, phase II investigation neoadjuvant apalutamide monotherapy and (RP) in the treatment D’Amico (NCT03124433). Materials methods Patients histologically-proven, adenocarcinoma received 240 mg once-daily 12 weeks followed by RP + /−lymphadenectomy. Primary outcome was pathological complete response (pCR)...
Sphingosine kinase 1 (SphK1) phosphorylates the membrane sphingolipid, sphingosine, to sphingosine-1-phosphate (S1P), an oncogenic mediator, which drives tumor cell growth and survival. Although SphK1 has gained increasing prominence as determinant in several cancers, its potential a therapeutic target colon cancer remains uncertain. We investigated clinical relevance of expression well inhibitory effects vitro.SphK1 human tissues was determined by immunohistochemistry clinicopathological...
// Chris W.D. Armstrong 1 , Pamela J. Maxwell Chee Wee Ong Kelly M. Redmond Christopher McCann Jessica Neisen George A. Ward 3 Gianni Chessari Johnson Nyree T. Crawford Melissa LaBonte Kevin Prise Tracy Robson 2 Manuel Salto-Tellez Daniel B. Longley David J.J. Waugh Movember Centre of Excellence, for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland School Pharmacy, Astex Pharmaceuticals, Cambridge, UK Correspondence to: DJJ Waugh, e-mail: d.waugh@qub.ac.uk...
Aims: Although earlier reports highlighted a tumor suppressor role for manganese superoxide dismutase (MnSOD), recent evidence indicates increased expression in variety of human cancers including aggressive breast carcinoma. In the present article, we hypothesized that MnSOD is significantly amplified carcinoma basal subtype, and targeting could be an attractive strategy enhancing chemosensitivity this highly cancer subtype. Results: Using MDA-MB-231 BT549 as model cell lines, show knockdown...
Ong C W, Kim L G, Kong H H, Low Y, Wang T T, Supriya S, Kathiresan M, Soong R & Salto‐Tellez M (2010) Histopathology 56 , 523–529 Computer‐assisted pathological immunohistochemistry scoring is more time‐effective than conventional scoring, but provides no analytical advantage Aims: Interpretation of primarily done through human visual while computer‐assisted relatively uncommon. This study aimed to examine (i) the level agreement between and immunoreactivity expression in colorectal...
Determination of HER2 protein expression by immunohistochemistry (IHC) and genomic status fluorescent in situ hybridisation (FISH) are important identifying a subset high HER2-expressing gastric cancers that might respond to trastuzumab. Although FISH is considered the standard for determination status, brightfield ISH being increasingly recognised as viable alternative. Also, impact expression/genomic heterogeneity on accuracy testing has not been well studied context biopsy samples.To...
Background Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility anti-human epidermal growth factor receptor 2 (anti-HER2) agents treatment this disease, with attendant need to identify suitable predictive biomarkers response treatment. Aims/methods The authors studied prevalence HER2 genomic amplification overexpression 85 ovarian tumours local patient cohort study, as well concordance rate...